Results 291 to 300 of about 457,600 (353)

Osteoclast‐Derived SLIT3 Mediates Osteoarthritis Pain and Degenerative Changes

Advanced Science, EarlyView.
In TMJ‐OA, osteoclasts play a significant role in promoting the growth of sensory nerves at the osteochondral interface. In early OA, TRAP+ osteoclast‐derived SLIT3 induces sensory nerve growth into the condylar cartilage. This nerve growth facilitates the development of pain associated with OA.
Weiwei Zhu, Wenpin Qin, Jialu Gao, Yihan Guo, Xiaoxiao Han, Zhangyu Ma, Xiaokang Zhang, Jie He, Jing Liu, Bo Gao, Changjun Li, Lina Niu, Jianfei Yan, Kai Jiao   +13 more
wiley   +1 more source

Synthetic Lethal Therapy Based on Dimorphism for Systemic Infection of Drug‐Resistant Candida albicans

Advanced Science, EarlyView.
To tackle the alarming mortality rate linked to Candida albicans infections, a synthetic lethal strategy precisely aimed at the two distinct forms of this fungus: yeast and hyphae is formulated. Ultimately, through the innovative use of macrophage membranes for drug delivery, the effectiveness of this strategy is substantially boosted while ...
Yang Gao, Jiahe Su, Jiawei Yuan, Qinyan Cao, Yue Wu, Yuyang Xiao, Guang Yang, Ruomu Xia, Jingpeng Yang, Yanan Li, Lina Wu, He Huang, Lingtong Meng   +12 more
wiley   +1 more source

Tislelizumab plus tyrosine kinase inhibitors with TACE improves survival in unresectable hepatocellular carcinoma with clinical predictors and manageable safety. [PDF]

Front Immunol
Wang F, Cao Z, Yu C, Li J, Li Q, Chang S, Zhang S, Wang S.   +7 more
europepmc   +1 more source

The Immune Microenvironment in Liver Cancer: From Analysis to Targeting

Advanced Science, EarlyView.
This review explores how smart nanomedicines overcome the immunosuppressive tumor microenvironment in liver cancer. It details targeted delivery strategies and immune reprogramming mechanisms, including remodeling abnormal physiology, modulating metabolism, and inducing immunogenic cell death. The article highlights the paradigm shift toward multimodal
Jiaming Lan, Hao Li, Jian Xue, Yourong Duan, Jin Sun, Meng Niu   +5 more
wiley   +1 more source

Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients. [PDF]

J Transl Med
Chai X, Li H, Yang M, Zeng J, Chen G, Li Y, Wang W, Liu Z, Li K, Zhang T, Wang S, Che N.   +11 more
europepmc   +1 more source

All Nanozyme‐Based Cascade Reactions for Biomedical Applications: from Self‐Cascading Nanozyme to Immobilized Cascade Nanozyme

Advanced Science, EarlyView.
This review introduces the development and classification of all‐nanozyme cascade reaction systems, highlighting mechanistic insights and research methods for understanding catalytic features and design principles. It provides detailed classifications, surveys recent applications in biosensing and therapy, and discusses the challenges that all‐nanozyme
Caixia Zhu, Congcong Jiang, Hian Kee Lee, Yuanjian Zhang, Sheng Tang   +4 more
wiley   +1 more source

BCR::ABL1 Tyrosine Kinase Inhibitors During Pregnancy, a Disproportionality Analysis of Vigibase. [PDF]

Clin Pharmacol Ther
Cabannes-Hamy A, Kabirian R, Jochum F, Bihan K, Dumas E, Coussy F, Laas E, Rousselot P, Choquet S, Uzunov M, Salomon L, Reyal F, Hamy AS, Gougis P.   +13 more
europepmc   +1 more source

Mechanism of Lenvatinib Resistance via Exosomal miRNA‐132/Nrf2 Axis in Hepatocellular Carcinoma

Annals of Gastroenterological Surgery, EarlyView.
Exosomal miRNA‐132 from LVT‐res HCC cells activated Nrf2 expression through the PTEN/GSK3β pathway in recipient cells. This cascade could induce drug resistance in non‐resistant HCC cells in the TME. ABSTRACT Introduction Lenvatinib is a multiple receptor tyrosine kinase inhibitor and a first‐line targeted therapy for hepatocellular carcinoma (HCC ...
Chie Takasu, Chiharu Nakasu, Yu Saito, Yuji Morine, Tetsuya Ikemoto, Shinichiro Yamada, Hiroki Teraoku, Mitsuo Shimada   +7 more
wiley   +1 more source

Tyrosine Kinase Inhibitors and Interstitial Lung Disease: A Disproportionality Analysis Using the European Post-marketing EudraVigilance Database. [PDF]

Drugs Real World Outcomes
Shah DR, Hart SP, Sykes DL.
europepmc   +1 more source

Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting. [PDF]

Future Oncol
Shah BD, Xue M, Furnback W, Yang K.
europepmc   +1 more source